Reduced PU.1 expression underlies aberrant neutrophil maturation and function in β-thalassemia mice and patients-Reference-Cited by-同舟云学术

Reduced PU.1 expression underlies aberrant neutrophil maturation and function in β-thalassemia mice and patients

Published:2017-06-08 Issue:23 Volume:129 Page:3087-3099
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Siwaponanan Panjaree¹²³,Siegers Jurre Ynze¹,Ghazali Razi¹,Ng Thian¹⁴,McColl Bradley¹,Ng Garrett Zhen-Wei¹⁵,Sutton Philip¹⁵⁶,Wang Nancy⁴,Ooi Isabelle¹⁴,Thiengtavor Chayada⁷,Fucharoen Suthat²,Chaichompoo Pornthip⁷,Svasti Saovaros²⁸,Wijburg Odilia⁴,Vadolas Jim¹⁶

Affiliation:

1. Murdoch Childrens Research Institute, The Royal Children’s Hospital, Parkville, VIC, Australia;

2. Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand;

3. Molecular Medicine Graduate Program, Faculty of Science, Mahidol University, Bangkok, Thailand;

4. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity,

5. Centre for Animal Biotechnology, Faculty of Veterinary and Agricultural Science, and

6. Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; and

7. Department of Pathobiology, Faculty of Science, and

8. Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand

Abstract

Key Points Aberrant neutrophil maturation is associated with reduced effector functions in β-thalassemia. PU.1, the key regulator of terminal neutrophil maturation, is dysregulated in β-thalassemia.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/23/3087/1400969/blood730135.pdf

Reference71 articles.

1. Thalassaemia;Higgs;Lancet,2012

2. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study;Taher;Blood Cells Mol Dis,2016

3. Malignancies and thalassemia: a review of the literature;Zanella;Ann N Y Acad Sci,2016

4. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives;Kremastinos;Circ Heart Fail,2010

5. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications;Ricerca;Mediterr J Hematol Infect Dis,2009

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 and β-thalassemia: in lieu of evidence and vague nexus;Annals of Hematology;2023-07-05

2. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions;Haematologica;2023-05-11

3. Chromosome conformation capture approaches to investigate 3D genome architecture in Ankylosing Spondylitis;Frontiers in Genetics;2023-01-25

4. Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients;Hematology Reports;2022-10-21

5. A comprehensive study of immune function and immunophenotyping of white blood cells from β‐thalassaemia/ HbE patients on hydroxyurea supports the safety of the drug;British Journal of Haematology;2022-10-11